Gynecologic Oncology

The FDA granted fast track designation to ADRX-0706 for locally advanced or metastatic squamous cell cervical cancer.

Adavosertib monotherapy demonstrated signs of antitumor activity in uterine serous carcinoma; however, the phase 2 starting dose was not well tolerated.

Shannon Westin, MD, MPH, FACOG, contextualizes data from an exploratory biomarker analysis of the phase 3 DUO-E trial in pMMR recurrent endometrial cancer.

Eighty percent of patients with early-stage dMMR solid tumors given neoadjuvant dostarlimab underwent nonoperative management of their disease.

Dostarlimab/chemotherapy was granted an expanded approval by Health Canada to treat patients with primary advanced or first recurrent endometrial cancer.

Yong Jae Lee, MD, PhD, discusses the clinical relevance of the preliminary safety of nivolumab for resectable mismatch repair–deficient endometrial cancer.

Linda R. Duska, MD, MPH, contextualizes updated OS and PFS2 findings from the second interim analysis of KEYNOTE-A18 in locally advanced cervical cancer.

Pamela T. Soliman, MD, MPH, discusses a phase 1 investigation of temsirolimus plus metformin in patients with recurrent endometrial cancer.

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

Panagiotis A. Konstantinopoulos, MD, PhD, discusses CRs achieved with letrozole, abemaciclib, and metformin in ER–positive endometriod endometrial cancer.

Chunyan Lan, MD, PhD, details the efficacy and safety of cadonilimab/lenvatinib in platinum-pretreated advanced endometrial cancer.

IHC staining is top of mind for the use of ADCs in cervical cancer management; however, the specific indications for each agent must be considered.

Rachel N. Grisham, MD, discusses the safety of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.

Tisotumab vedotin was granted approval by the EU for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Yong Jae Lee, MD, PhD, discusses key efficacy outcomes with nivolumab monotherapy in completely surgically resectable dMMR endometrial cancer.

Linda R. Duska, MD, MPH, discusses OS and PFS2 outcomes with concurrent pembrolizumab and chemoradiotherapy in high-risk advanced cervical cancer.

Chunyan Lan, MD, PhD, discusses data with cadonilimab plus lenvatinib in advanced endometrial cancer, as well as next steps for evaluating the combination.

Christian Marth, MD, PhD, and John Chan, MD, discuss ongoing research to watch in endometrial cancer.

Christian Marth, MD, PhD, and John Chan, MD, discuss antibody-drug conjugates and agents under evaluation in endometrial cancer.

Christian Marth, MD, PhD, and John Chan, MD, discuss subgroup data for frontline lenvatinib/pembrolizumab in endometrial cancer after perioperative chemotherapy.

Christian Marth, MD, PhD, and John Chan, MD, discuss frontline chemoimmunotherapy combinations in advanced endometrial cancer.

Christian Marth, MD, PhD, and John Chan, MD, discuss data for frontline lenvatinib plus pembrolizumab in advanced endometrial cancer.

Ramez N. Eskander, MD, discusses the key efficacy findings and future implications of the NIVEC trial of nivolumab in resectable dMMR endometrial cancer.

Tisotumab vedotin has received Japanese approval for advanced cervical cancer following chemotherapy.